0001714899-23-000109.txt : 20230719
0001714899-23-000109.hdr.sgml : 20230719
20230719171017
ACCESSION NUMBER: 0001714899-23-000109
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230717
FILED AS OF DATE: 20230719
DATE AS OF CHANGE: 20230719
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schuth Alexander O.
CENTRAL INDEX KEY: 0001724311
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38311
FILM NUMBER: 231097443
MAIL ADDRESS:
STREET 1: C/O DENALI THERAPEUTICS INC.
STREET 2: 151 OYSTER POINT BLVD., 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Denali Therapeutics Inc.
CENTRAL INDEX KEY: 0001714899
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463872213
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 866-8548
MAIL ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
wk-form4_1689801007.xml
FORM 4
X0508
4
2023-07-17
0
0001714899
Denali Therapeutics Inc.
DNLI
0001724311
Schuth Alexander O.
C/O DENALI THERAPEUTICS INC.
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
COFO and Secretary
0
Common Stock
2023-07-17
4
M
0
10000
5.28
A
538691
I
See footnote
Common Stock
2023-07-17
4
S
0
10000
29.60
D
528691
I
See footnote
Common Stock
2023-07-18
4
S
0
9702
30.01
D
518989
I
See footnote
Common Stock
131822
D
Stock Option (right to buy)
5.28
2023-07-17
4
M
0
10000
0
D
2027-03-07
Common Stock
10000
68937
D
Exercised shares were issued to the Schuth Family Trust.
The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.33 to $29.94 per share. Upon request by the Commission staff, the Issuer, or a
securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.04 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Includes 1,030 shares acquired under the ESPP Purchase on May 31, 2023.
Includes 119,156 RSUs.
25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter.
/s/ Alexander Schuth
2023-07-19